AstraZeneca PLC

BMV:AZN1 N Stock Report

Market Cap: Mex$4.7t

AstraZeneca Valuation

Is AZN1 N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AZN1 N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
Mex$3.71k
Fair Value
22.5% undervalued intrinsic discount
20
Number of Analysts

Below Fair Value: AZN1 N (MX$2873.68) is trading below our estimate of fair value (MX$3708.91)

Significantly Below Fair Value: AZN1 N is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZN1 N?

Key metric: As AZN1 N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AZN1 N. This is calculated by dividing AZN1 N's market cap by their current earnings.
What is AZN1 N's PE Ratio?
PE Ratio32.4x
EarningsUS$7.04b
Market CapUS$229.78b

Price to Earnings Ratio vs Peers

How does AZN1 N's PE Ratio compare to its peers?

The above table shows the PE ratio for AZN1 N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.7x
LAB B Genomma Lab Internacional. de
16.4x19.0%Mex$26.6b
MRK Merck
12.3x7.6%US$210.0b
NOVN Novartis
17.7x7.0%CHF 189.9b
ROG Roche Holding
28.3x14.6%CHF 236.9b
AZN1 N AstraZeneca
32.4x16.5%Mex$182.8b

Price-To-Earnings vs Peers: AZN1 N is expensive based on its Price-To-Earnings Ratio (32.4x) compared to the peer average (18.7x).

Price to Earnings Ratio vs Industry

How does AZN1 N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

22 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AZN1 N 32.4xIndustry Avg. 22.3xNo. of Companies86PE01632486480+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AZN1 N is expensive based on its Price-To-Earnings Ratio (32.4x) compared to the Global Pharmaceuticals industry average (22.3x).

Price to Earnings Ratio vs Fair Ratio

What is AZN1 N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZN1 N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AZN1 N's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AZN1 N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$3,591.87
0%
12.9%Mex$4,767.84Mex$2,764.17n/a20
Feb ’26Mex$2,873.68
Mex$3,550.74
+23.6%
13.6%Mex$4,568.32Mex$2,630.61n/a19
Jan ’26n/a
Mex$3,573.71
0%
13.4%Mex$4,595.15Mex$2,702.38n/a19
Dec ’25n/a
Mex$3,617.28
0%
13.3%Mex$4,656.52Mex$2,725.59n/a19
Nov ’25n/a
Mex$3,736.17
0%
15.3%Mex$5,254.28Mex$2,771.53n/a19
Oct ’25n/a
Mex$3,633.34
0%
14.6%Mex$5,108.60Mex$2,733.38n/a20
Sep ’25n/a
Mex$3,556.74
0%
11.7%Mex$4,446.33Mex$2,784.35n/a21
Aug ’25n/a
Mex$3,357.35
0%
11.6%Mex$4,206.84Mex$2,634.38n/a22
Jul ’25n/a
Mex$3,207.14
0%
12.1%Mex$4,147.04Mex$2,524.12n/a22
Jun ’25n/a
Mex$2,922.91
0%
12.3%Mex$3,818.43Mex$2,331.76n/a22
May ’25n/a
Mex$2,804.55
0%
13.5%Mex$3,747.15Mex$2,234.10n/a20
Apr ’25n/a
Mex$2,681.11
0%
14.9%Mex$3,695.01Mex$1,994.91n/a21
Mar ’25n/a
Mex$2,764.95
0%
14.3%Mex$3,833.05Mex$2,048.29n/a21
Feb ’25n/a
Mex$2,825.47
0%
12.1%Mex$3,725.70Mex$2,336.50Mex$2,873.6821
Jan ’25n/a
Mex$2,815.31
0%
10.4%Mex$3,616.74Mex$2,286.61n/a21
Dec ’24n/a
Mex$2,852.80
0%
10.3%Mex$3,651.71Mex$2,308.72n/a21
Nov ’24n/a
Mex$3,005.43
0%
9.9%Mex$3,896.09Mex$2,443.11n/a22
Oct ’24n/a
Mex$2,960.33
0%
9.3%Mex$3,761.75Mex$2,465.65n/a22
Sep ’24n/a
Mex$2,864.34
0%
10.4%Mex$3,667.48Mex$2,268.01n/a23
Aug ’24n/a
Mex$2,892.08
0%
10.4%Mex$3,743.20Mex$2,277.18n/a23
Jul ’24n/a
Mex$2,905.14
0%
9.6%Mex$3,735.13Mex$2,295.04n/a22
Jun ’24n/a
Mex$2,942.79
0%
9.9%Mex$3,829.80Mex$2,353.21n/a22
May ’24n/a
Mex$2,948.10
0%
10.0%Mex$3,906.40Mex$2,418.94n/a22
Apr ’24n/a
Mex$2,849.43
0%
10.3%Mex$3,739.18Mex$2,218.62n/a23
Mar ’24Mex$2,323.99
Mex$2,815.08
+21.1%
14.1%Mex$3,843.14Mex$1,512.95n/a25
Feb ’24Mex$2,323.99
Mex$2,896.64
+24.6%
15.1%Mex$3,963.50Mex$1,499.74n/a25
Analyst Price Target
Consensus Narrative from 20 Analysts
Mex$3.45k
Fair Value
16.8% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 20:06
End of Day Share Price 2025/01/29 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AstraZeneca PLC is covered by 77 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
John EadeArgus Research Company